Sign Out
Pharmacology: ZAVICEFTA (ceftazidime-avibactam): Broad-spectrum Gram-negative coverage with consistent dosing across indications.
ZAVICEFTA has in vitro activity against Pseudomonas aeruginosa resistance to ceftazidime and ESBL producing bacteria.
ZAVICEFTA is a combination of ceftazidime, an antipseudomonal cephalosporin, and avibactam, a novel β-lactamase inhibitor.
Ceftazidime: A broad-spectrum, third-generation antipseudomonal cephalosporin with a well-characterised efficacy and tolerability profile.
Avibactam: A non β-lactamase inhibitor which allows ceftazidime to maintain activity in the presence of certain resistance.
The combination of ceftazidime and avibactam provides broad-spectrum Gram-negative coverage, including in vitro activity against.
ZAVICEFTA is active against a broad range of Gram-negative resistance mechanisms, including class A (e.g. ESBL and KPC), class C (e.g. AmpC) and some class D (including OXA-48) β-lactamases.
*Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and is not able to inhibit many class D enzymes.
